Recent advances toward the clinical application of PTH (1-34) in fracture healing. Academic Article uri icon

Overview

abstract

  • PTH 1-34, an active form of parathyroid hormone, has been shown to enhance osteoblastic bone formation when administered as a daily subcutaneous injection. The effect of the intermittent administration of PTH (1-34) is an uncoupling of bone turnover with an increase in bone mass and density and decrease in risk of vertebral and nonvertebral fractures. While PTH (1-34) has been used clinically to increase bone mass and reduce fracture risk in postmenopausal women with osteoporosis, there is increasing evidence that PTH (1-34) may promote fracture healing. Animal studies have demonstrated accelerated callus formation with enhanced remodeling and biomechanical properties of the healing fracture. Given these effects, PTH (1-34) will likely be used clinically to enhance fracture union in poor healing situations such as osteoporosis and recalcitrant nonunions.

publication date

  • March 17, 2009

Identity

PubMed Central ID

  • PMC2744747

Scopus Document Identifier

  • 0036001310

Digital Object Identifier (DOI)

  • 10.1080/01926230252929882

PubMed ID

  • 19290582

Additional Document Info

volume

  • 5

issue

  • 2